Navigation Links
Herpes drug inhibits HIV in patients infected with both viruses
Date:9/15/2008

This release is available in French.

Researchers at the U.S. National Institutes of Health (NIH), McGill University and other institutions have discovered how a simple antiviral drug developed decades ago suppresses HIV in patients who are also infected with herpes. Their study was published in the Sept. 11 issue of the journal Cell Host and Microbe.

An NIH research team led by Dr. Leonid Margolis made the initial discovery, while Dr. Matthias Gotte, Associate Professor in Biochemical Virology at McGill's Department of Microbiology and Immunology, along with colleagues at Emory University, helped explain the precise molecular mechanisms.

According to Dr. Gotte, HIV/herpes co-infection rates are very high and carry significant health burdens for those patients who are already coping with HIV.

"In co-infected individuals, HIV disease progression is enhanced by the presence of herpes," he explained. "Why this is the case is not clear, but there's a lot of evidence for it. Moreover, if you're infected with HIV and herpes, it makes it easier for you to transmit HIV to other people. And if you're infected with herpes alone, it makes it easier for you to acquire HIV."

Though it was long-believed that acyclovir was an ineffective drug against HIV, it was often prescribed to co-infected patients in the hope of indirectly treating HIV by reducing the herpes load. Surprisingly, the NIH team discovered that in the presence of herpes virus HHV-6, acyclovir actually attacks HIV directly and is able to suppress its reproduction.

Acyclovir is a "prodrug," which is converted into its active form only after it is administered to a patient. The research team demonstrated that the herpes virus contains an enzyme not present in HIV and it is this enzyme that converts acyclovir into a compound capable of attacking in HIV. Acyclovir by itself is simply inactive against HIV and therefore the drug can only work in people infected with both viruses.

The researchers are hopeful this discovery may open a new front in the war on HIV, particularly in parts of the developing world where rates of co-infection are extremely high.

"No anti-retroviral kills HIV completely," Dr. Gotte said. "We need to administer at least three drugs to hold it in check. This potentially gives us another weapon in the armory, and it's cheap and accessible, which matters a lot in the developing world."


'/>"/>

Contact: Mark Shainblum
mark.shainblum@mcgill.ca
514-398-2189
McGill University
Source:Eurekalert

Related biology news :

1. Herpes virus link to complications in pregnancy
2. Penn researchers shine the light of venus to learn how the herpes virus invades cells
3. A compound extracted from olives inhibits cancer cells growth and prevents their appearance
4. Majority of osteoporosis patients not receiving calcium and vitamin D with treatment
5. A home early warning system for cardiac patients
6. New sensory devices will aid Parkinsons and stroke patients
7. Unlocking mystery of why dopamine freezes Parkinsons patients
8. CMV infections affect more than just patients with compromised immune systems, researchers find
9. Smothered genes combine with mutations to yield poor outcome in cancer patients
10. Cross fire from the brain makes patients tremble
11. New treatment approach promising for lymphoma patients in the developing world
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... ... April 29, 2016 , ... Proove ... excited to announce the launch of the Proove Health Foundation . The ... education to promote the use of personalized medicine for tackling the nation’s most-pressing ...
(Date:4/29/2016)... and San Diego, CA (PRWEB) , ... April 29, 2016 , ... ... Stem Cell Foundation (NSCF) to support the development of a patient-specific stem cell therapy ... Andrés Bratt-Leal in the lab of Dr. Jeanne Loring at The Scripps Research Institute ...
(Date:4/28/2016)... April 28, 2016 Q ... the Company,s CEO  was featured in an article ... When VCs Fear To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... magazine is an essential business journal for ... emerging biotechs to Big Pharmas. Their content is ...
(Date:4/28/2016)... Windsor, Connecticut (PRWEB) , ... April 28, 2016 ... ... Morris Group, Inc., will hold an open house for regional manufacturers at its ... and displays from Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 ...
Breaking Biology Technology: